U.S. government forces Chinese divestiture in health data startup PatientsLikeMe: report

China's technology spending will grow to reach US$256 billion this year (Image daoleduc / iStockPhoto)
Chinese investments in U.S. businesses have dropped 90% in the past two years, from $46 billion in 2016 to $4.8 billion in 2018, CNBC reported. (daoleduc / iStockPhoto)

Real-world data gatherer PatientsLikeMe has to shop for a new buyer—and quickly—after the Trump administration ordered a Chinese company to divest its majority stake, according to a report from CNBC.

In 2017, PatientsLikeMe partnered with the Shenzhen, China-based iCarbonX—a genomics data firm supported by the conglomerate Tencent—and raised more than $100 million in a series C round with iCarbonX serving as lead investor.

iCarbonX agreed to provide multi-omics sequencing services, while PatientsLikeMe would serve as “a cornerstone” of its health technology collaboration, which aimed to merge and analyze biological and patient-generated information using artificial intelligence.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: PatientsLikeMe and Biogen reveal positive data from wearable device study for MS

The Cambridge, Massachusetts-based PatientsLikeMe links together about 700,000 people with those who have similar conditions to share health experiences and gather data for research studies. Other companies participating in iCarbonX’s alliance included SomaLogic, HealthTell, AOBiome, GALT, Imagu and Robustnique, according to a release.

However, the Treasury Department’s Committee on Foreign Investment in the United States (CFIUS) has been scrutinizing Chinese investments in American companies.

RELATED: Trade war tariffs now touch nearly every U.S. medical device sold in China

CFIUS ordered the divestiture under a 2008 statute that allows the president to review and block any merger that could result in a foreign person or company controlling a U.S. company. That was expanded last year to include foreign investments and minority stakes, in addition to takeovers, the article said.

While CFIUS previously focused on multibillion-dollar international acquisitions, the actions singling out a small company could have harsh effects on the startup sphere by chilling international investment.

RELATED: PatientsLikeMe adds AstraZeneca to growing list of big-name clients

CNBC reported that Chinese expenditures in U.S. businesses have dropped 90% in the past two years, from $46 billion in 2016 to $4.8 billion in 2018, according to data from the Rhodium Group, which said another $20 billion in divestitures is still pending.

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.